A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Public ClinicalTrials.gov record NCT06979596. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.
Study identification
- NCT ID
- NCT06979596
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Interventions
- Opevesostat Drug
- Fludrocortisone/ Fludrocortisone acetate Drug
- Dexamethasone/Dexamethasone acetate Drug
- Rescue Medications Drug
- Fulvestrant Drug
- Exemestane Drug
- Megestrol acetate/Medroxyprogesterone acetate Drug
- Tamoxifen Drug
- Letrozole Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 10, 2025
- Primary completion
- Nov 3, 2027
- Completion
- Nov 3, 2027
- Last update posted
- Aug 27, 2026
2025 – 2027
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Womens Cancer Care ( Site 0037) | Anchorage | Alaska | 99508 | Recruiting |
| Mount Sinai Cancer Center ( Site 0009) | Miami Beach | Florida | 33140 | Recruiting |
| TRIALS 365 ( Site 0022) | Shreveport | Louisiana | 71103 | Recruiting |
| Mary Lanning Healthcare ( Site 0019) | Hastings | Nebraska | 68901 | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0021) | Hackensack | New Jersey | 07601 | Recruiting |
| Rockefeller Outpatient Pavilion ( Site 0002) | New York | New York | 10022 | Recruiting |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0008) | Columbus | Ohio | 43210 | Recruiting |
| Baylor College of Medicine Medical Center ( Site 0004) | Houston | Texas | 77030 | Recruiting |
| Harris Health System ( Site 0040) | Houston | Texas | 77054 | Recruiting |
| Mays Cancer Center ( Site 0039) | San Antonio | Texas | 78229 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06979596, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06979596 live on ClinicalTrials.gov.